Patients whose sarcomas hadgene mutation or gene amplification of both CD133 and Nanog had significantlyworse disease-free survival compared to patients whose sarcomas did not havegene mutation or gene amplification of CD133 and Nanog (Fig. 1F). This evidence concerns the gene NANOG and sarcoma.